drugset
drugset / Trial / NCT05796765

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

NCT05796765 ↗

Phase 2 Terminated 43 enrolled MiMedx Group, Inc. NBCD A/S · collabRho, Inc. · collabUnited BioSource, LLC · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of the 40 mg and 100 mg doses of allogeneic micronized dehydrated human amnion/chorion membrane (micronized DHACM) injectable compared to 0.9% sodium chloride injection, placebo control for the treatment of knee osteoarthritis

Timeline

Start
2023-03-24
Primary completion
2023-12-15
Completion
2023-12-15

Outcome

Outcome not reported

Stopped: “Study discontinued early by Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject DHACM Unknown 40 mg —
Subject DHACM Unknown 100 mg —

Indications

osteoarthritis, knee